Veloxis Increases Share Capital in Connection with Exercise

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Veloxis Increases Share Capital in Connection with Exercise of Warrants

Company Announcement no. 20/2016

To: NASDAQ OMX Copenhagen A/S                         Copenhagen, Denmark, 6 September 2016

     

Veloxis Increases Share Capital in Connection with Exercise of Warrants

Veloxis Pharmaceuticals A/S announces that the company's capital has been increased by 1,500,000 new shares with a nominal value of DKK 0.10 each corresponding to nominal DKK 150,000 as a consequence of the exercise of warrants by former employees of the company granted under the company's warrant program.

As a result of the employee’s investment in the company proceeds to Veloxis Pharmaceuticals A/S from the capital increase amounts to DKK 525,000.

The subscription prices for the new shares is DKK 0.35 per share of nominal DKK 0.10.

The new shares will be listed on NASDAQ Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 170,057,388.10 divided into shares of DKK 0.10 each.

Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S. The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.

 

For more information, please contact:

Craig A. Collard           

President & CEO                      

Phone: +1 919 524 4317                    

Email: cac@veloxis.com                       

 

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA and maintains a second corporate office in Edison, New Jersey, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 205

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 196

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 204

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 405

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 193

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 253

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 330

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 238

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

CorMedix Achieves 52-Week High Amidst Business Expansion Strategies

Updated Category News Views 122

CorMedix Stock Reaches New Heights CorMedix Inc. has recently celebrated a milestone by reaching a new 52-week high, with shares hitting $10.15. This significant achievement comes as part of a broader trend of notable expansion and investor confidence in the pharmaceutical and medical device sector. Over the past year, CorMedix's stock has increased by an impressive...

Continue Reading
Norway's Wealth Fund Shifts Ethics Standards Amid Gaza Conflict

Updated Category News Views 148

Norway's Wealth Fund Takes a Stand on Ethical Investments Norway's $1.7 trillion wealth fund is currently navigating a challenging ethical landscape as it considers pulling investments from companies associated with operations in the occupied Palestinian territories. The fund's Council on Ethics has adopted a stricter interpretation of its ethical standards, which could...

Continue Reading
Bonduelle's Monthly Share and Voting Rights Update

Updated Category News Views 120

Overview of Bonduelle's Monthly Share and Voting Rights Update Bonduelle, a prominent player in the food industry, is well-known for its commitment to providing high-quality vegetable products. Headquartered in an innovative facility, their corporate structure includes a significant capital invested which showcases their strong market presence. Latest Information on...

Continue Reading
Innovative Partnership Launches Unique Aging and Cancer Research Institute

Updated Category News Views 193

Innovative Partnership in Cancer Research The Mark Foundation for Cancer Research (MFCR) and the Samuel Waxman Cancer Research Foundation (SWCRF) have entered a groundbreaking collaboration to create the Samuel Waxman Institute for Aging & Cancer. This institute will serve as the first dedicated global center exploring how aging impacts cancer risk throughout a person's...

Continue Reading
Market Overview: Nasdaq Surges as Stocks Show Mixed Trends

Updated Category News Views 201

Market Overview: Nasdaq Shows Strength The U.S. stock markets experienced a mixed performance recently, with the Nasdaq Composite recording a notable gain of over 50 points. This uptick brings attention to sector volatility and specific stock behaviors that investors should closely monitor. Daily Market Trends After the markets opened, the Dow Jones Industrial Average saw...

Continue Reading